09 Sep Mirus Bio
Laura Juckem, Ph.D., Vice President of Scientific Operations
Oct. 12 | 4:45pm | BlueRock Therapeutics Ballroom
Mirus Bio, founded in 1995, is a research-centric biotechnology company focused on nucleic acid delivery. Numerous in vitro and in vivo delivery technologies have been developed and commercialized to address cutting-edge applications such as RNA interference, mRNA delivery, CRISPR/Cas, and recombinant virus manufacture. Our most recent breakthrough, the TransIT-VirusGEN® GMP Transfection Reagent and the complementary VirusGEN® GMP complex formation and enhancer solutions, support robust and scalable manufacture of adeno-associated virus (AAV) and lentivirus for gene and cell therapy applications. Mirus has recently partnered with Gamma Biosciences to further augment the commercialization of the VirusGEN® transient transfection platform for large-scale virus manufacture and the growing gene therapy field. Mirus takes pride in the fact that its team continues to push the boundaries of transfection technology to enable groundbreaking discoveries, and the development of life-changing biotherapeutics that empower scientists throughout the world.